Cochlear nucleus monitoring predicts hearing after schwannoma surgery; fully implanted cochlear implant trial passes six-month mark

• Technology Oct 23, 2026
  Dorsal cochlear nucleus monitoring predicts hearing after vestibular schwannoma surgery in 153 adults
  A retrospective Journal of Neurosurgery study of 153 adults who had hearing preservation retrosigmoid vestibular schwannoma surgery monitored the dorsal cochlear nucleus action potential (DNAP) with a four-contact depth electrode. Serviceable hearing was achieved in 41.2% at five to seven days and in 40.9% of 137 patients at six months. DNAP preservation was the most consistent independent predictor of hearing outcomes, and DNAP showed consistently higher sensitivity than auditory brainstem response (ABR) monitoring at six months, the authors said.
  Sources: Journal of Neurosurgery, Crossref, PubMed
• Technology Oct 20, 2026
  Envoy Medical's fully implanted Acclaim cochlear implant passes six-month mark in U.S. pivotal trial
  Envoy Medical said Oct. 20 that its U.S. pivotal trial of the investigational, fully implanted Acclaim cochlear implant passed the six-month follow-up visit, the halfway point of the final data-collection stage, in which each participant is followed for 12 months. The device received Food and Drug Administration (FDA) breakthrough device designation in 2019, and the company has submitted two of four planned modules of its premarket approval application. Envoy said a potential FDA decision could come by the end of 2027 or early 2028; no results were reported.
  Source: Envoy Medical (BioSpace)

The weekly innovation roundup for otolaryngology, published every Sunday for the week before; every item links to its sources. Latest otolaryngology news · All specialties